• SHOP
  • QUOTE
InVivoMAb anti-human/rat HER2 (neu)
Clone Catalog # Category
7.16.4 BE0277 InVivoMab Antibodies
$300 - 3080

The 7.16.4 monoclonal antibody reacts with human and rat HER2 (human epidermal growth factor receptor 2) also known as neu peptide, CD340, ErbB-2, and p185. HER2 is a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity that is part of several cell surface receptor complexes. HER2 lacks an identified ligand however, the kinase can be activated in the absence of a ligand when overexpressed. HER2 is a proto-oncoprotein that is commonly overexpressed on a variety of different tumors. Approximately 40% of human breast cancers overexpress HER2. HER2 overexpression is associated with poorer overall survival rates, shorter times to disease progression, and increased resistance to chemotherapy. Because of these clinical characteristics anti-HER2 monoclonal antibody therapy is now a standard for the treatment of advanced breast cancers that overexpress HER2. The 7.16.4 antibody has been shown to inhibit the growth of HER2-overexpressing tumors both in vitro and in vivo.

Isotype

Mouse IgG2a

Recomended Isotype Control(s) InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen

neu-transfected NIH 3T3 cells

Reported Applications
  • in vivo HER2/neu inhibition
  • in vitro HER2/neu inhibition
  • Immunoprecipitation
  • Immunofluorescence
  • Flow cytometry
Endotoxin
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
Purity
  • >95%
  • Determined by SDS-PAGE
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Sterility

0.2 μM filtered

Production

Purified from tissue culture supernatant in an animal free facility

Purification

Protein G

Storage

Undiluted at 4°C in the dark